CEO, Appili Therapeutics & BioNova Chairperson
Mr. Sullivan has over 15 years’ experience working with early stage biotechnology companies and has raised over $37M in private equity and non-dilutive government funding in biotechnology. Most recently he was Chief Executive Officer at DeNovaMed Inc., a biotechnology company focused on development of Gram-negative and Gram-positive antibiotics. Previously, he was Chief Operating Officer at Viron Therapeutics, a biopharmaceutical company developing a novel immunotherapy and recipient of the Prix Galien Award for Biotechnology. At Viron, he and his team completed development of the Company’s lead program through Phase 2 clinical development with Series A and B financing from a syndicate of international venture capital including two pharma-venture participants. He is an active mentor and volunteer advisor for several start-up biotechnology companies. Mr. Sullivan received a BSc in Immunology from Dalhousie University, a Graduate Certificate in Biotechnology from McGill University and an MBA from the Richard Ivey School of Business (UWO).